Advanced Instruments, a Patricia Industries subsidiary and manufacturer of analytical instruments for the biopharmaceutical and clinical markets, has agreed to acquire Nova Biomedical, a manufacturer of analytical instruments and consumables that are vital in guiding the treatment of patients and the development of biotechnology therapeutics.

Following the closing of the transaction, both companies will operate under the Nova Biomedical name, with a diverse portfolio of analytical instruments, reagents, and services. 

Byron Selman, President & CEO of Advanced Instruments, will lead the combined business, while Nova Biomedical’s founding shareholders, Frank Manganaro, CEO, and Dr. Chung-Chang Young, EVP of R&D, will stay with the company in a consulting capacity. 

Selman said, “The combination of our technologies, R&D strength, global sales network, dedicated teams, and commitment to innovation will advance our collective ability to support customer workflows within various stages of drug development and bioprocessing and expand our footprint within the hospital and other healthcare settings, guiding patient care with our diversified product portfolio and supporting our growing customer base.”

Closing is subject to regulatory approval and is expected during the third quarter of 2025.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.